**template for Peer Review comments**

**Technical series on synthetic biology**

|  |
| --- |
| **Contact information** |
| **Surname:** | Coppens |
|  |  |
| **Given Name:** | Fanny  |
|  |  |
| **Government** | Belgium |
| **(if applicable):** |  |
|  |  |
| **Organization:** | Sciensano |
|  |  |
| **E-mail:** | Fanny.Coppens@sciensano.be / hsegers@naturalsciences.be  |
|  |  |
| **Comments on the Technical Series on Synthetic Biology** |
| **Page #** | **Line #** | **Comment** |
| 22 | 1 | "DBTL" instead of "DBLT" in the title above the figure |
| 27 | 29 | This work illustrates how *E.coli* can be engineered for the production of natural and non-natural flavonoid targets : Dunstan MS et al, (2020). Engineering Escherichia coli towards de novo production of gatekeeper (2S)-flavanones: naringenin, pinocembrin, eriodictyol and homoeriodictyol. Synthetic Biology, In Press, DOI: 10.1093/synbio/ysaa012 |
| 29 | 2-28 | The following reference could be added : https://www.nature.com/articles/s41589-020-00697-z |
| 34 | 39 | In the area of CAR T-cells therapy, allogeneic CAR- T cell therapy has the potential to pave the way for further breakthrough in the treatment of cancer. See Depil et al., 2020, Nature reviews Drug Discovery 19, 185-199 (2020). Research in this area could be mentioned when addressing advances in clinical therapeutics. |
| 57 | 46 | A reference elaborating on plausible pathways for potential harm via problem formulation could be added: Connelly et al., (2021) Malaria J 20(1):170 - doi: 10.1186/s12936-021-03674-6 |
| 59 | 10 | "breeding" instead of "breading" |
| 167 | 44 | Link is broken, please replace it with the correct link: <https://www.biosafety.be/sites/default/files/120911_doc_synbio_sbb_final.pdf>  |

Please submit your comments to secretariat@cbd.int.